FY2026 Individual Financial Statements: Operating Loss Widens, Net Loss Narrows
-
Sales KRW 29.75bn (↑1.2% YoY)
-
Operating loss KRW 4.13bn (from -3.08bn, loss widened 34.3%)
-
Net loss KRW 2.08bn (from -13.19bn, loss narrowed 84.2%)
-
Operating loss increased due to higher inventory valuation allowance; net loss decreased due to lower non-recurring losses
-
No capital erosion, total equity KRW 71.03bn
KOSPI Filing Information
-
Filing: Change in Sales or Profit Structure of 30% (15% for Large Corporations) or More
-
Company: ORIENTBIO (002630)
-
Submission: ORIENTBIO Inc.
-
Receipt: 05-15-2026
-
Under KRX KOSPI Market Division